CorcoranRB, AndreT, AtreyaCE, et al.. Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov2018;8:428–443.
CorcoranRB, AndreT, AtreyaCE, . Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov 2018;8:428–443.2943169910.1158/2159-8290.CD-17-1226)| false
SiravegnaG, LazzariL, CrisafulliG, et al.. Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. Cancer Cell2018;34:148–162.
SiravegnaG, LazzariL, CrisafulliG, . Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. Cancer Cell 2018;34:148–162.2999049710.1016/j.ccell.2018.06.004)| false
BrannonAR, VakianiE, SylvesterBE, et al.. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol2014;15:454.
RyserMD, MinBH, SiegmundKD, et al.. Spatial mutation patterns as markers of early colorectal tumor cell mobility. Proc Natl Acad Sci U S A2018;115:5774–5779.
RyserMD, MinBH, SiegmundKD, . Spatial mutation patterns as markers of early colorectal tumor cell mobility. Proc Natl Acad Sci U S A 2018;115:5774–5779.2976005210.1073/pnas.1716552115)| false
HeWZ, HuWM, WangF, et al.. Comparison of mismatch repair status between primary and matched metastatic sites in patients with colorectal cancer. J Natl Compr Canc Netw2019;17:1174–1183.
HeWZ, HuWM, WangF, . Comparison of mismatch repair status between primary and matched metastatic sites in patients with colorectal cancer. J Natl Compr Canc Netw 2019;17:1174–1183.3159014810.6004/jnccn.2019.7308)| false
OvermanMJ, McDermottR, LeachJL, et al.. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol2017;18:1182–1191.
OvermanMJ, McDermottR, LeachJL, . Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017;18:1182–1191.2873475910.1016/S1470-2045(17)30422-9)| false
OvermanMJ, LonardiS, WongKYM, et al.. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol2018;36:773–779.
